CDC Official: Hepatitis C Virus Can Be Eliminated in the US

Video

"We have drugs now that used to take one pill to several pills a day for 2-3 months, you can cure 95% of people living with hepatitis C. The issue is getting those persons identified who are living with this silent infection."

At the Conference on Retroviruses and Opportunistic Infections (CROI 2017) in Seattle, Washington, John W. Ward, MD, with the Centers for Disease Control and Prevention (CDC) discussed evidence supporting the fact that the hepatitis C virus can, indeed, be eliminated in the United States by 2030.

"We have drugs now that used to take one pill to several pills a day for two to three months, you can cure 95% of people living with hepatitis C. The issue is getting those persons identified who are living with this silent infection," said Ward. He shared that half don't know their status among the 3.5 million people living with hepatitis C in the country, so the first order of business is getting them tested, made aware of their infection, then referred to a specialist.

Ward and his team are particularly interested in baby boomers (people born between 1945 and 1965). They have a six times higher risk of having this virus than other adults, because they were young adults before the virus was discovered and before prevention measures were in place. Ward highlighted that now 70% of them have moderate-to-severe liver disease - many of them are unaware of it. "We really want to send a strong message out that all providers who have baby boomers in their practice should provide this test to them.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.